Results 31 to 40 of about 196,164 (338)

Electroretinographic improvement after rituximab therapy in a patient with autoimmune retinopathy

American Journal of Ophthalmology Case Reports, 2016
Purpose: To describe the effect of rituximab on full-field electroretinography (ERG) in a patient with nonparaneoplastic autoimmune retinopathy (npAIR). Observations: A 58-year-old male patient with visual complaints, positive anti-retinal antibodies and
Gunay Uludag, Sumru Onal, Serra Arf, Isil Sayman Muslubas, Fatih Selcukbiricik, Aylin Koc Akbay, Nil Molinas Mandel   +6 more
doaj   +1 more source

Advances in the Management of Primary Membranous Nephropathy and Rituximab-Refractory Membranous Nephropathy

Frontiers in Immunology, 2022
Primary membranous nephropathy (pMN) is an auto-immune disease characterized by auto-antibodies targeting podocyte antigens resulting in activation of complement and damage to the glomerular basement membrane.
Maxime Teisseyre, Marion Cremoni, Sonia Boyer-Suavet, Caroline Ruetsch, Daisy Graça, V. Esnault, Vesna Brglez, B. Seitz-Polski   +7 more
semanticscholar   +1 more source

Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia

Haematologica, 2013
Rituximab is an effective treatment for autoimmune cytopenias associated with chronic lymphocytic leukemia. Despite the incorporation of rituximab into fludarabine-based chemotherapy regimens, the incidence of autoimmune cytopenias has remained high ...
Clifton C. Mo, Ndegwa Njuguna, Paul V. Beum, Margaret A. Lindorfer, Berengere Vire, Elinor Lee, Gerald Marti, Wyndham H Wilson, Ronald P. Taylor, Adrian Wiestner   +9 more
doaj   +1 more source

Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus

Annals of Internal Medicine, 2021
BACKGROUND B-cell depletion with rituximab is commonly used for patients with systemic lupus erythematosus (SLE) that is refractory to conventional therapy, but it yields variable responses.
M. Shipa, A. Embleton-Thirsk, M. Parvaz, L. Santos, Patrick Muller, Kashfia Chowdhury, D. Isenberg, C. Doré, C. Gordon, M. Ehrenstein, D. Isenberg, C. Gordon, D. D'cruz, N. Jordan, B. Parker, L. Lightstone, A. Salama, D. Pyne, Christopher J. Edwards, B. Griffiths, E. Vital, B. Rhodes, C. Yee, M. Akil, P. Topham, N. Gullick   +25 more
semanticscholar   +1 more source

Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial

Journal of Hematology & Oncology, 2012
Background The randomized phase 3 LYM3001 trial in relapsed follicular lymphoma (FL) demonstrated higher overall (ORR) and complete response (CR) rates and prolonged progression-free survival (PFS) with bortezomib-rituximab versus rituximab.
Zinzani Pier, Khuageva Nuriet K, Wang Huaqing, Garicochea Bernardo, Walewski Jan, Van Hoof Achiel, Soubeyran Pierre, Caballero Dolores, Buckstein Rena, Esseltine Dixie-Lee, Theocharous Panteli, Enny Christopher, Zhu Eugene, Elsayed Yusri A, Coiffier Bertrand   +14 more
doaj   +1 more source

Coding joint: kappa-deleting recombination excision circle ratio and B cell activating factor level: predicting juvenile dermatomyositis rituximab response, a proof-of-concept study

BMC Rheumatology, 2022
Background This pilot study’s primary aim was to determine if oligoclonal B cell expansion in children with Juvenile Dermatomyositis (JDM) predicts response to Rituximab therapy.
Elisa Ochfeld, Victoria Hans, Wil Marin, Najah Ahsan, Gabrielle Morgan, Lauren M. Pachman, Amer Khojah   +6 more
doaj   +1 more source

Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study

Journal of Clinical Oncology, 2021
PURPOSE The double-blind, randomized, placebo-controlled phase III iNNOVATE study showed sustained efficacy of ibrutinib-rituximab in Waldenström's macroglobulinemia (WM). Here, we present the final analysis from iNNOVATE.
C. Buske, A. Tedeschi, J. Trotman, R. García-Sanz, D. MacDonald, V. Leblond, B. Mahé, C. Herbaux, J. Matous, C. Tam, L. Heffner, M. Varettoni, M. Palomba, C. Shustik, E. Kastritis, S. Treon, J. Ping, B. Hauns, I. Arango‐Hisijara, M. Dimopoulos   +19 more
semanticscholar   +1 more source

CD47 Blockade by Hu5F9‐G4 and Rituximab in Non‐Hodgkin's Lymphoma

New England Journal of Medicine, 2018
Background The Hu5F9‐G4 (hereafter, 5F9) antibody is a macrophage immune checkpoint inhibitor blocking CD47 that induces tumor‐cell phagocytosis. 5F9 synergizes with rituximab to eliminate B‐cell non‐Hodgkin's lymphoma cells by enhancing macrophage ...
R. Advani, I. Flinn, L. Popplewell, A. Forero, N. Bartlett, N. Ghosh, J. Kline, M. Roschewski, A. LaCasce, G. Collins, T. Tran, J. Lynn, J. Chen, J. Volkmer, B. Agoram, Jie Huang, R. Majeti, I. Weissman, C. Takimoto, M. Chao, Sonali M. Smith   +20 more
semanticscholar   +1 more source

Subcutaneous versus intravenous administration of rituximab: pharmacokinetics, CD20 target coverage and B-cell depletion in cynomolgus monkeys. [PDF]

PLoS ONE, 2013
The CD20-specific monoclonal antibody rituximab (MabThera(®), Rituxan(®)) is widely used as the backbone of treatment for patients with hematologic disorders. Intravenous administration of rituximab is associated with infusion times of 4-6 hours, and can
Cheng-Ping Mao, Martin R Brovarney, Karim Dabbagh, Herbert F Birnböck, Wolfgang F Richter, Christopher J Del Nagro   +5 more
doaj   +1 more source

Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children.

New England Journal of Medicine, 2020
BACKGROUND Rituximab added to chemotherapy prolongs survival among adults with B-cell cancer. Data on its efficacy and safety in children with high-grade, mature B-cell non-Hodgkin's lymphoma are limited.
V. Minard-Colin, A. Aupérin, M. Pillon, G. Burke, D. Barkauskas, K. Wheatley, Rafael F Delgado, S. Alexander, A. Uyttebroeck, C. Bollard, J. Zsiros, M. Csóka, B. Kazanowska, A. Chiang, R. Miles, A. Wotherspoon, P. Adamson, G. Vassal, C. Patte, T. Gross   +19 more
semanticscholar   +1 more source